Abstract B044: CBO-001, a potential first and best-in-class ADC targeting L1CAM/CD171 with potent anti-tumor efficacy in SCLC and neuroendocrine tumors
Year: 2025
Type: conference-abstract
Source: Molecular Cancer Therapeutics
Authors: Dominik Brücher, Christian Geraths, Michael Hackebeil, Franziska Strütt, Daniela Winkler, Christoph Schäffer, Kathrin Locher, Ruggero Della Bitta
Institution: CIS Pharma (Switzerland)
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4415444581